GlassScriptPhysician profile
Marlene Schmitz
NPI 1790937498
$4,864.72
in general payments reported to CMS, 2019-2025
60 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $569 · 2023: $1,194 · 2024: $1,161 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $385.69 | 2021-2025 | Imdelltra (Amg757), Lumakras, Kyprolis |
| Abbvie INC. | $273.66 | 2021-2025 | |
| Janssen Biotech, INC. | $273.02 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $267.25 | 2021-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pharmacosmos Therapeutics INC. | $236.14 | 2021-2025 | Monoferric, Cosela |
| Novartis Pharmaceuticals Corporation | $198.42 | 2023-2025 | |
| Incyte Corporation | $186.72 | 2021-2025 | Pemazyre, Jakafi |
| Glaxosmithkline, LLC. | $183.67 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $181.50 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.84 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Eisai INC. | $152.32 | 2021-2025 | |
| Daiichi Sankyo INC. | $141.63 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Seagen INC. | $117.33 | 2021-2023 | Adcetris, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $112.94 | 2023-2025 | Ninlaro, Alunbrig, Iclusig |
| Pfizer INC. | $103.27 | 2021-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $102.22 | 2021-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $95.63 | 2021-2025 | Opdivo, Eliquis |
| Janssen Pharmaceuticals, INC | $88.61 | 2021-2024 | Xarelto |
| Genzyme Corporation | $86.19 | 2021-2025 | |
| Taiho Oncology, INC. | $83.68 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $81.46 | 2022-2025 | Clonoseq |
| Astellas Pharma US INC | $76.04 | 2021-2024 | Xospata |
| Stemline Therapeutics INC. | $72.34 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $70.13 | 2023-2025 | Tivdak |
| Celgene Corporation | $70.10 | 2023-2025 | Reblozyl |
| Genentech USA, INC. | $69.39 | 2024-2025 | Tecentriq, Alecensa, Itovebi |
| Regeneron Healthcare Solutions, INC. | $64.07 | 2021-2025 | Libtayo |
| Global Blood Therapeutics, INC. | $57.38 | 2021-2022 | |
| Blueprint Medicines Corporation | $54.40 | 2023-2025 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $52.31 | 2021-2025 | Onivyde |
| Lilly USA, LLC | $49.34 | 2021-2025 | Jaypirca, Verzenio |
| Alexion Pharmaceuticals, INC. | $46.84 | 2021-2025 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $42.89 | 2022 | |
| Sumitomo Pharma America, INC. | $36.75 | 2023-2024 | Orgovyx |
| Array Biopharma INC | $35.65 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Agios Pharmaceuticals, INC. | $34.87 | 2025 | Pyrukynd |
| Foundation Medicine, INC. | $32.54 | 2023 | |
| Geron Corporation | $32.42 | 2025 | Rytelo |
| Morphosys, US INC. | $30.37 | 2022 | |
| Rigel Pharmaceuticals, INC. | $29.98 | 2024 | Tavalisse, Rezlidhia |
| Cti Biopharma Corp. | $29.83 | 2022-2023 | Vonjo |
| Karyopharm Therapeutics INC. | $29.22 | 2021-2023 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.90 | 2021-2024 | Gilotrif |
| Caris Mpi, INC. | $28.24 | 2025 | Mi Cancer Seek |
| Sobi, INC | $27.90 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $27.13 | 2022-2023 | Imbruvica |
| Tersera Therapeutics LLC | $22.15 | 2024 | Xermelo |
| Emmaus Medical, INC. | $20.39 | 2023 | Endari |
| Spectrum Pharmaceuticals INC. | $19.55 | 2023 | Rolvedon |
| Exelixis INC. | $19.00 | 2024 | Cabometyx |
| Kite Pharma, INC. | $16.66 | 2025 | Yescarta |
| Servier Pharmaceuticals LLC | $16.63 | 2024 | |
| Myriad Genetic Laboratories, INC. | $15.86 | 2024 | Precisetumor |
| Pharmaessentia USA Corporation | $15.34 | 2024 | Besremi |
| Emd Serono, INC. | $15.08 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $14.82 | 2025 | Sancuso |
| Welch Allyn | $14.55 | 2021 | |
| Baxter Healthcare | $13.23 | 2022 | |
| Sun Pharmaceutical Industries INC. | $12.85 | 2022 | |
| Heron Therapeutics, INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Schmitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.